Abstract

The increased vancomycin minimum inhibitory concentration values (MICs) for methicillin-resistant Staphylococcus aureus (MRSA) isolates are associated with treatment failure and mortality of MRSA infections. In the present study, 553 non-duplicate MRSA isolates from various specimens of patients with infections at a Chinese tertiary hospital from January 2003 to December 2014, were selected randomly for investigating the shift of vancomycin MICs determined by E-test method. The percentages of the MRSA isolates with vancomycin MICs of ≥2.0, 1.5, 1.0, and ≤0.75 mg/L were 16.3% (90/553), 38.5% (213/553), 35.6% (197/553), and 9.9% (55/553), respectively. The highest geometric mean MIC (GM MIC) value (1.648 mg/L) and the lowest GM MIC (0.960 mg/L) were found in the first year (2003) and the last year (2014) over the study period, with significant difference (p < 0.05). The GM MICs over the study period fluctuated by year, with the elevated values in 2005, 2011, and 2013 and the decreased values in other years relative to the respective former year. The vancomycin GM MIC (1.307 mg/L) for MRSA isolates from sputum was the highest relative to that for the MRSA isolates from other specimens. By contrast, the vancomycin GM MIC value (1.156 mg/L) for MRSA isolates from pus was the lowest, with similar value to that for the isolates from blood. The vancomycin GM MICs in period I (2003–2005), period II (2006–2008), period III (2009–2011), and period IV (2012–2014) were 1.501, 1.345, 1.177, and 1.139 mg/L, respectively, with the continuous decreased trend. Compared with period I, the vancomycin GM MIC for MRSA isolates in period IV was significantly lower (p < 0.01), with a 1.318- fold decrease. The percentages of the isolates with vancomycin MIC ≥2 mg/L in four periods were 25, 15.6, 15.2, and 12%, respectively, with a continuous decrease. While the percentages of the isolates with vancomycin MIC ≤0.75 mg/L in four periods increased from 1.7% in period I to 19.3% in period IV. Taken together, a decreased trend in vancomycin MICs for MRSA isolates from a Chinese tertiary teaching hospital has been found. This pnenomenon was mainly associated with a decrease in the proportion of the MRSA isolates with vancomycin MIC ≥2 mg/L and an increase in the proportion of the MRSA isolates with vancomycin MIC ≤0.75 mg/L.

Highlights

  • Staphylococcus aureus, MRSA, is an important cause of infections including skin and soft tissue infections, foreignbody infections, pneumonia, septic arthritis, endocarditis, osteomyelitis, sepsis, and bloodstream infections both in hospitals and community settings (David and Daum, 2010)

  • Of 553 MRSA clinical isolates, 98.0% were susceptible to vancomycin, while 2.0% (11 isolates) with vancomycin MIC = 3 mg/L were intermediate susceptible to vancomycin

  • The vancomycin geometric mean MIC (GM MIC) over the study period fluctuated by year, with the increased results in 2005, 2011, and 2013 and the decreased results in other years relative to the respective former year

Read more

Summary

Introduction

Staphylococcus aureus, MRSA, is an important cause of infections including skin and soft tissue infections, foreignbody infections, pneumonia, septic arthritis, endocarditis, osteomyelitis, sepsis, and bloodstream infections both in hospitals and community settings (David and Daum, 2010). The emergence of VISA, hVRSA, and VRSA results in the failure of vancomycin treatment for serious MRSA infections, which is becoming an important public health threat. The increased vancomycin MIC values for MRSA isolates were associated with treatment failure and mortality (Martin et al, 2010). Because the high failure rate of vancomycin treatment for MRSA infections is associated with higher vancomycin MICs, the CLSI reduced the vancomycin susceptibility breakpoint for S. aureus from MIC value of 4–2 mg/L to improve the predictive susceptibility result (CLSI, 2016). The elevated vancomycin MICs among MRSA clinical isolates in China should be of concern. The primary objective of this study was to evaluate the shift in vancomycin MICs for MRSA clinical isolates over a 12-year period (2003–2014) at a tertiary teaching hospital in China

Objectives
Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.